

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1. Name and Address

Jolt Health Inc. (the “**Company**”)
1780-355 Burrard Street
Vancouver, BC
V6C 2C8

Item 2. Date of Material Change

February 26, 2025

Item 3. News Release

The news release describing the material change was disseminated on February 20, 2025 through Access Newswire and filed on SEDAR.

Item 4. Summary of Material Change

The Company announced that it is proceeding with a consolidation of its common shares (each, a “Share”) on the basis of twenty (20) pre-consolidation Shares for one (1) post-consolidation Share (the “Consolidation”). The shareholders approved the Consolidation at the Annual and Special Meeting held on December 30, 2024, and the Board of Directors approved and confirmed the consolidation ratio on January 7, 2025.

The Company currently has 127,289,723 Shares issued and outstanding. Accordingly, once the Consolidation is effective, the Company will have 6,364,486 Shares issued and outstanding, assuming there are no other changes in the issued capital of the Company.

The Company intends to also proceed with consolidating its outstanding warrants and options on a ratio of twenty (20) to one (1), with the result that each consolidated warrant and option will entitle the holder to acquire one Share at an exercise price of twenty (20) times its original exercise price.

The effective date of the consolidation is February 26, 2025.

Item 5. Full Description of Material Change

5.1 Full Description of Material Change

The Company announced it is proceeding with a consolidation of its common shares (each, a “Share”) on the basis of twenty (20) pre-consolidation Shares for one (1) post-consolidation Share (the “Consolidation”). The shareholders approved the Consolidation at the Annual and Special Meeting held on December 30, 2024, and the Board of Directors approved and confirmed the consolidation ratio on January 7, 2025.

The Company currently has 127,289,723 Shares issued and outstanding. Accordingly, once the Consolidation is effective, the Company will have 6,364,486 Shares issued and outstanding, assuming there are no other changes in the issued capital of the Company.

The Company also proceeded with consolidating its outstanding warrants and options on a ratio of twenty (20) to one (1), with the result that each consolidated warrant and option will entitle the holder to acquire one Share at an exercise price of twenty (20) times its original exercise price.

The Consolidation will provide the Company with increased flexibility to seek additional financing opportunities.

The effective date of the consolidation will be February 26, 2025.

5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

No information has been omitted in respect of this material change.

Item 8. Executive Officer

The following executive officer of the Company is knowledgeable about the material change disclosed in this report and may be contacted as follows:

Gerald Tritt, CEO
Telephone: (604) 343-2977

Item 9. Date of Report

February 26, 2025